Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
about
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.Risk factors and chemoprevention in Barrett's esophagus--an update.GERD assessment including pH metry predicts a high response rate to PPI standard therapyPrevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma.Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysisTreatment of uncomplicated reflux diseaseAn update on the available treatments for non-erosive reflux disease.Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men.Necrotizing sialometaplasia-like change of the esophageal submucosal glands is associated with Barrett's esophagus.Helicobacter pylori infection in children: management and pharmacotherapy.Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis.Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.Age at onset of GERD symptoms predicts risk of Barrett's esophagus.Endoscopic findings of esophagogastric junction in children.Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device.Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study.Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?Anxiety and depression in patients with gastroesophageal reflux disorder.Gastro-oesophageal reflux disease: symptoms, erosions, and Barrett's--what is the interplay?Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.Progression of specialized intestinal metaplasia at the cardia to macroscopically evident Barrett's esophagus: an entity of concern in the ProGERD study.Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus.Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment.Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study.Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa.Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis.Prevalence and risk factors of Barrett's esophagus in Korea
P2860
Q27332349-29750FA0-9C02-43D8-8FA1-C70B712286ABQ34201351-9B980F5A-3991-43BA-8D7E-CDD81FCAA9FAQ34549954-FB005E39-386B-4BAE-93E7-E8ADE428F638Q35291990-2486AC1C-E19C-4F22-BA92-3C8620A3638FQ36190840-49E1439C-3124-476B-A1EB-380A9EC92443Q36204260-84FA957D-6B6B-4EC7-8EC8-4DAC162112D7Q36349598-F07EBC0E-EFBB-448E-84B7-A1C0D3C9B4C0Q36711453-6F2F2A5D-219A-451F-9191-2842134B79F2Q36904153-1A8968B3-9231-407E-84D4-31751113EAE0Q37099003-867D5733-14CB-4A9B-97AB-A842D8C7B5B4Q37379013-FFD67638-A431-4B92-AD11-5F1E7DF1C506Q37466737-042687CB-94D4-41B6-A42A-8EBFF2C5C56EQ37678177-4FC263E0-9C58-48CD-80EB-3420DC46D032Q38829143-BA744F05-7E91-4B98-AB32-3B01E0E95A66Q38946177-8276C33E-E722-4CC2-9B30-004464E12ACBQ39256525-F764884F-330E-4C1B-9774-0D9C34F58383Q39345800-F2D9334D-EE36-4465-B107-1511575038FCQ42052089-A61AAAE3-41D8-42B6-BF27-B162AAA16B70Q42110833-F9C23187-5ED0-4C8F-A8F1-35AE3FC05316Q42170103-D120F824-1270-4C98-BFFC-4AF59BF15AFDQ42288370-6D3D7025-1061-4814-9073-0FB7A2817419Q42488877-DDEB703A-4CDA-400F-8108-A55A7325F08AQ46742251-81ED8257-E4CF-4CD5-BBB3-826E021A9406Q51734244-D758560F-7FAE-4D51-8C64-AC2D8EA66E20Q52935129-94CF22C7-8007-4C20-9874-504C196BB461Q53442448-117D4267-62AB-4391-BE23-423E5C61E9D3Q57212245-EBA47C7F-E885-411B-8334-49BCA6B7BE05
P2860
Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prognostic influence of Barret ...... report from the ProGORD study.
@ast
Prognostic influence of Barret ...... report from the ProGORD study.
@en
type
label
Prognostic influence of Barret ...... report from the ProGORD study.
@ast
Prognostic influence of Barret ...... report from the ProGORD study.
@en
prefLabel
Prognostic influence of Barret ...... report from the ProGORD study.
@ast
Prognostic influence of Barret ...... report from the ProGORD study.
@en
P2093
P2860
P356
P1433
P1476
Prognostic influence of Barret ...... report from the ProGORD study.
@en
P2093
D Jaspersen
O Junghard
P Malfertheiner
W Meyer-Sabellek
P2860
P304
P356
10.1136/GUT.2004.042143
P407
P577
2005-06-01T00:00:00Z